Bharat Biotech on course to have 26,000 volunteers for Phase-3 clinical trials of Covaxin

The company statement has come after an expert panel of India's central drug authority recommended granting permission for restricted use of Covaxin in emergency situation, especially in the context of infection by mutant strains.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2X0PTix
via IFTTT